---
figid: PMC3413411__nihms262374f1
figtitle: PI3K-AKT-mTOR signaling pathway
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC3413411
filename: nihms262374f1.jpg
figlink: /pmc/articles/PMC3413411/figure/F1/
number: F1
caption: PI3K-AKT-mTOR signaling pathway. A more detailed description of the biology
  of the mTOR has revealed the presence of two complexes and has led to the development
  of new drugs targeting specifically these complexes. In addition, feedback loops
  have been better characterized.Phosphatydilinositol-3-kinase, PI3K; mammalian target
  of rapamycin, mTOR; mTOR complex, mTORC; tuberous sclerosis complex, TSC; eukaryotic
  initiation factor 4E binding protein 1, 4E-BP1; ribosomal S6 kinase 1, S6K1; Ras
  homolog enriched in brain, Rheb; serum- and glucocorticoid-induced protein kinase-1,
  SGK1; protein kinase C, PKC; insulin receptor-substrate 1, IRS-1; mitogen–activated
  protein kinase kinase, MEK; receptor tyrosine-kinase, RTK; regulatory-associated
  protein of mTOR, Raptor; proline-rich AKT substrate of 40 kDa, PRAS40; phosphatase
  and tensin homolog, PTEN; Phosphatidylinositol (4,5)-bisphosphate, PIP2; Phosphatidylinositol
  (3,4,5)-trisphosphate, PIP3; phosphoinositide-dependent kinase-1, PDK1.
papertitle: Pushing the envelope in the mTOR pathway. The second generation of inhibitors.
reftext: Eduardo Vilar, et al. Mol Cancer Ther. ;10(3):395-403.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9666344
figid_alias: PMC3413411__F1
figtype: Figure
redirect_from: /figures/PMC3413411__F1
ndex: 04fcc685-ded0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3413411__nihms262374f1.html
  '@type': Dataset
  description: PI3K-AKT-mTOR signaling pathway. A more detailed description of the
    biology of the mTOR has revealed the presence of two complexes and has led to
    the development of new drugs targeting specifically these complexes. In addition,
    feedback loops have been better characterized.Phosphatydilinositol-3-kinase, PI3K;
    mammalian target of rapamycin, mTOR; mTOR complex, mTORC; tuberous sclerosis complex,
    TSC; eukaryotic initiation factor 4E binding protein 1, 4E-BP1; ribosomal S6 kinase
    1, S6K1; Ras homolog enriched in brain, Rheb; serum- and glucocorticoid-induced
    protein kinase-1, SGK1; protein kinase C, PKC; insulin receptor-substrate 1, IRS-1;
    mitogen–activated protein kinase kinase, MEK; receptor tyrosine-kinase, RTK; regulatory-associated
    protein of mTOR, Raptor; proline-rich AKT substrate of 40 kDa, PRAS40; phosphatase
    and tensin homolog, PTEN; Phosphatidylinositol (4,5)-bisphosphate, PIP2; Phosphatidylinositol
    (3,4,5)-trisphosphate, PIP3; phosphoinositide-dependent kinase-1, PDK1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pten
  - pi
  - S6k
  - ras
  - Ras64B
  - Ras85D
  - Tsc1
  - Akt
  - Pdk1
  - Raf
  - Lst8
  - Rheb
  - Mtor
  - Tor
  - Dsor1
  - raptor
  - rictor
  - Erk7
  - rl
  - PRAS40
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Thor
  - IRS1
  - PTEN
  - PI3
  - RICTOR
  - RPS6KB1
  - KRAS
  - HRAS
  - NRAS
  - TSC1
  - CCL26
  - AKT1
  - AKT2
  - AKT3
  - PDK1
  - PDPK1
  - DEPTOR
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MLST8
  - RHEB
  - RHEBP1
  - MTOR
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - SGK1
  - AKT1S1
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - EIF4EBP1
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
